MVI, Sanaria explore new approaches to malaria vaccine

11/4/2009 | Thaindian News

The PATH Malaria Vaccine Initiative has teamed up with Sanaria to develop an experimental malaria vaccine that will use a weakened form of the Plasmodium falciparum parasite. The vaccine currently is in human trials in the U.S. Other vaccine approaches being considered by the researchers include preventing the transmission of the disease from mosquitoes to humans.

View Full Article in:

Thaindian News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA